Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
Would you treat a sputum culture positive for Aspergillus niger despite an atypical CT chest and a negative serum galactomannan in an immunosuppressed patient who is too high risk for bronchoscopy?
Related Questions
What further evaluation do you pursue for patients who present with vague symptoms such as subjective fevers or intermittent night sweats, who have no pulmonary symptoms but have a positive IGRA?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
How would you treat a patient with psoriatic arthritis who developed disseminated histoplasmosis while on adalimumab and previously failed all non-biologic DMARDs?
How do you manage resistant infections that persist after stopping antibiotic therapy in patients with non-CF bronchiectasis?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Do you administer prophylactic antibiotics to prevent VAP following intubation in patients with acute brain injury?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
